CN106860857A - 一种治疗猪黄白痢疾的中西药制剂 - Google Patents
一种治疗猪黄白痢疾的中西药制剂 Download PDFInfo
- Publication number
- CN106860857A CN106860857A CN201710029015.4A CN201710029015A CN106860857A CN 106860857 A CN106860857 A CN 106860857A CN 201710029015 A CN201710029015 A CN 201710029015A CN 106860857 A CN106860857 A CN 106860857A
- Authority
- CN
- China
- Prior art keywords
- pig
- yellowish
- chinese
- treating
- western medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 208000001848 dysentery Diseases 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 241000282898 Sus scrofa Species 0.000 claims abstract description 61
- 210000002966 serum Anatomy 0.000 claims abstract description 26
- 241000196324 Embryophyta Species 0.000 claims abstract description 17
- 239000010231 banlangen Substances 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960005229 ceftiofur Drugs 0.000 claims abstract description 6
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 claims abstract description 6
- 235000015424 sodium Nutrition 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 6
- UZQVYLOFLQICCT-SCSAIBSYSA-N (R)-goitrin Chemical compound C=C[C@@H]1CNC(=S)O1 UZQVYLOFLQICCT-SCSAIBSYSA-N 0.000 claims description 6
- 239000004380 Cholic acid Substances 0.000 claims description 6
- UZQVYLOFLQICCT-UHFFFAOYSA-N Goitrin Natural products C=CC1CNC(=S)O1 UZQVYLOFLQICCT-UHFFFAOYSA-N 0.000 claims description 6
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 6
- 229960002471 cholic acid Drugs 0.000 claims description 6
- 235000019416 cholic acid Nutrition 0.000 claims description 6
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 241001131796 Botaurus stellaris Species 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 239000003011 anion exchange membrane Substances 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 230000005611 electricity Effects 0.000 claims description 3
- 238000000909 electrodialysis Methods 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000013190 sterility testing Methods 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 108010070514 Keratin-1 Proteins 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 102000005713 Keratin-1 Human genes 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- RFLHUYUQCKHUKS-JUODUXDSSA-M Ceftiofur sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 RFLHUYUQCKHUKS-JUODUXDSSA-M 0.000 abstract description 15
- 229960004467 ceftiofur sodium Drugs 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 241000282887 Suidae Species 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 6
- 241000589893 Brachyspira hyodysenteriae Species 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100040487 Keratin, type I cytoskeletal 13 Human genes 0.000 description 1
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 1
- 108010065070 Keratin-13 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000027909 hemorrhagic diarrhea Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1748—Keratin; Cytokeratin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种治疗猪痢疾的药剂，具体涉及一种治疗猪黄白痢疾的中西药制剂，该制剂以特制猪血清为溶剂，每10ml特制猪血清中溶解0.15‑1.2g头孢噻呋钠得到，特制猪血清由3月龄猪连续4‑5天仅饲喂青贮相思藤，然后断粮7天，断粮期间，每天仅饲饮板蓝根水煮剂，断粮期结束后，剖杀放血，分离得到的血清，特制猪血清中的有效成分与头孢噻呋钠配合，能有效解决细菌对头孢噻呋钠产生耐药性的问题，并同时提高了头孢噻呋钠作用和药效。
Description
技术领域
本发明涉及一种治疗猪痢疾的药剂，具体涉及一种治疗猪黄白痢疾的中西药制剂。
背景技术
猪痢疾是猪的一类肠道常见病，其特征为大肠粘膜发生卡他性出血性炎症进而发展为纤维素性坏死性肠炎，在临床上表现为粘液性或粘液出血性下痢，本病的原发性病原体为猪痢疾密螺旋体，病猪和带菌猪是本病的传染源，其带菌率高，带菌时间可长达70天以上，头孢噻呋钠作为治疗猪痢疾的一种药物，经常被用作治疗猪痢疾使用，但随着头孢噻呋钠使用频繁和大剂量使用，使得头孢噻呋钠作用效力减小，甚至产生耐药性，影响了治疗效果。
发明内容
本发明的目的在于提供一种治疗猪黄白痢疾的中西药制剂。
本发明采用的技术方案为，一种治疗猪黄白痢疾的中西药制剂，该制剂以特制猪血清为溶剂，每10ml特制猪血清中溶解0.15-1.2g头孢噻呋钠得到，具体制作时，
选取3月龄大健康无病害的公猪，连续4-5天仅饲喂青贮相思藤，然后断粮7天，断粮期间，每天仅饲饮板蓝根水煮剂，断粮期结束后，剖杀放血，分离血清，按比例溶解头孢噻呋钠，经无菌检测及生物学安全检测后，得到治疗猪黄白痢疾的中西药制剂按每5ml/每支分装入容器中，4℃保存。
其中，板蓝根水煮剂由板蓝根与水按1:100-150的重量比混合后，大火煮沸后，小火煎煮50-55分钟得到；
其中，青贮相思藤制作时，在花期，割取相思藤茎叶，浸渍于保鲜护色液中，并灌入真空度为200-220mm/Hg的罐内，贮存3个月以上得到；
所述保鲜护色液由富碘卤水用阴离子交换膜和BPM-Ⅰ型双极膜组成的两隔室双极膜电渗析处理后得到，电渗析电压为22-26V，物料流量为8-9L/h。
所述每g特制猪血清中含胆酸1.3-1.6mg，蛋白多糖5-5.5mg、表告依春2.6-3mg、β-谷甾醇1-1.5mg、角蛋白12-15mg、酪氨酸4.8-5mg。
本发明有益效果在于，本发明采用特制猪血清与头孢噻呋钠协同使用作为注射剂治疗猪黄白痢疾，能够有效抑杀猪痢疾密螺旋体，灭杀猪体内大肠杆菌、沙氏门菌、金黄色葡萄球菌，且可清除肠胃湿热，排除体内湿毒，对治疗猪黄白痢有较好的疗效，且无毒副作用，疗程短，用量少，治愈率较高，痊愈率可达到99.2%，治愈率可达到100%，并可预防再次感染；
其中，特制猪血清中的有效成分与头孢噻呋钠配合，能有效解决细菌对头孢噻呋钠产生耐药性的问题，并同时提高了头孢噻呋钠作用和药效；
其中，将相思藤茎叶，浸渍于由富碘卤水制作得到的保鲜护色液中，能够有效延长相思藤茎叶贮存时间，贮存期可达12个月，贮存期间，相思藤茎叶呈现出较为鲜绿的色泽和鲜嫩的口感；
公猪经连续饲喂4-5天的相思藤茎叶能有效将血液和肠道内毒素排出，以提高饲喂板蓝根水煮剂期间对板蓝根中有效成分的吸收，进而提高特制猪血清中有效成分的含量。
具体实施方式
实施例1、 一种治疗猪黄白痢疾的中西药制剂，该制剂以特制猪血清为溶剂，每10ml特制猪血清中溶解1g头孢噻呋钠得到，具体制作时，
选取3月龄大健康无病害的公猪，连续5天仅饲喂青贮相思藤，然后断粮7天，断粮期间，每天仅饲饮板蓝根水煮剂，断粮期结束后，剖杀放血，分离血清，按比例溶解头孢噻呋钠，经无菌检测及生物学安全检测后，得到治疗猪黄白痢疾的中西药制剂按每5ml/每支分装入容器中，4℃保存；
其中，板蓝根水煮剂由板蓝根与水按1:120的重量比混合后，大火煮沸后，小火煎煮53分钟得到；
其中，青贮相思藤制作时，在花期，割取相思藤茎叶，浸渍于保鲜护色液中，并灌入真空度为210mm/Hg的罐内，贮存3个月以上得到；
所述保鲜护色液由富碘卤水用阴离子交换膜和BPM-Ⅰ型双极膜组成的两隔室双极膜电渗析处理后得到，电渗析电压为25V，物料流量为8.3L/h；
所述每g特制猪血清中含胆酸1.44mg，蛋白多糖5.1mg、表告依春2.8mg、β-谷甾醇1.2mg、角蛋白13mg、酪氨酸4.9mg。
以下结合具体临床试验对本发明进一步说明：
临床试验1：
实验动物：
随机从同一养殖场选取同一品系3月龄大健康无病害的公猪共20头，随机分为A、B两组，每组各10头，
对A组公猪连续5天仅饲喂青贮相思藤，然后断粮7天，断粮期间，每天仅饲饮板蓝根水煮剂，断粮期结束后，剖杀放血，分离血清，检测血清中平均胆酸、蛋白多糖、表告依春、β-谷甾醇、角蛋白、酪氨酸这几种有效成分的含量；
对B组公猪断粮7天，断粮期间，每天仅饲饮板蓝根水煮剂，断粮期结束后，剖杀放血，分离血清，检测血清中平均胆酸、蛋白多糖、表告依春、β-谷甾醇、角蛋白、酪氨酸这几种有效成分的含量；
其中青贮相思藤、板蓝根水煮剂均按照实施例1中的方法制作，结果见下表1：
| 组别 | 胆酸 | 蛋白多糖 | 表告依春 | β-谷甾醇 | 角蛋白 | 酪氨酸 |
| A | 1.44mg | 5.1mg | 2.8mg | 1.2mg | 13mg | 4.9mg |
| B | 0.21mg | 1.0mg | 0.05mg | 0.17mg | 2.2mg | 0.44mg |
由表1可知，试验公猪饲喂板蓝根水煮剂前连续饲喂5天青贮相思藤，能有效提高公猪对板蓝根水煮剂有效成分的吸收和利用。
临床试验2：
实验动物：随机选取患病成猪只100头；
实验药物：由实施例1制备方法制作得到的中西药制剂；
实验方法：
将100头患猪按体重随机分为四组，每组25头；
A组为空白对照组，不给予药物治疗；
B组注射实施例1得到的中西药制剂，用法：肌肉注射，每1kg体重5mg，一日1次，连用3日；
C组用实施例1方法制作得到的特制猪血清，用法：肌肉注射，每1kg体重5mg，一日1次，连用3日；
D组用注射用头孢噻呋钠进行治疗，每10ml头孢噻呋钠注射液中含1g头孢噻呋钠，用法：肌肉注射，每1kg体重5mg，一日1次，连用3日；
治疗开始后，每日记录患猪身体变化情况和死亡动物分布，治疗10天后统计治疗效果，其中：
无效：指10天后，患猪症状无明显改变，仍保持治疗前的症状。
有效：指10天后，患猪症状有改变，症状优于治疗前的效果。
治愈：指10天后，症状消失，患猪恢复健康。其数字包括在有效数字中。
结束时有症状：指10天后，患猪仍有一定的症状，其症状表现优于治疗前或无改观，患猪没有治愈。其数字已包含在无效头数与有效头数的数字中。
相对增重率：指使用药物后相对于对空白照组的增重率。
试验结果如表2所示：
| 组别 | 无效头数 | 有效头数 | 治愈头数 | 结束时有症状猪头数 | 死亡头数 | 相对增重率 |
| A | 25 | - | - | 7 | 18 | - |
| B | 0 | 25 | 25 | 0 | 0 | 83.8% |
| C | 22 | 3 | 0 | 25 | 0 | 57.4% |
| D | 8 | 17 | 13 | 15 | 0 | 50.5% |
由上表可知，采用实施例1中西药制剂治疗猪黄白痢疾有显著效果，并能有效提高猪发病期增重率，实施例1特制猪血清对治疗猪黄白痢疾无明显作用，但能有效提高猪发病期增重率，仅采用头孢噻呋钠注射液治疗猪黄白痢疾效果不佳。
临床试验3：临床试验2中B组猪连续用药3天后停止用药，停药期间不再饲喂或注射任何治疗药物，并于停药7天后采集病猪的粪便拭子，
猪痢疾密螺旋体检：连续用药12天，测停药后第4天采集病猪的粪便拭子，PCR扩增猪痢疾密螺旋体特异性DNA片段，检测用药后病猪的猪痢疾密螺旋体携带情况，结果见表3：
| 组别 | 用药前PCR阳性率 | 用药第3天PCR阳性率 | 停药第7天PCR阳性率 |
| B | 98% | 2% | 0% |
由上表可知，采用实施例1中西药制剂对抑杀猪痢疾密螺旋体效果明显。
Claims (5)
1.一种治疗猪黄白痢疾的中西药制剂，其特征在于，
该制剂以特制猪血清为溶剂，每10ml特制猪血清中溶解0.15-1.2g头孢噻呋钠得到；具体制作时，
选取3月龄大健康无病害的公猪，连续4-5天仅饲喂青贮相思藤，然后断粮7天，断粮期间，每天仅饲饮板蓝根水煮剂，断粮期结束后，剖杀放血，分离血清，按比例溶解头孢噻呋钠，经无菌检测及生物学安全检测后，得到治疗猪黄白痢疾的中西药制剂按每5ml/每支分装入容器中，4℃保存。
2.根据权利要求1所述的一种治疗猪黄白痢疾的中西药制剂，其特征在于，
所述板蓝根水煮剂由板蓝根与水按1:100-150的重量比混合后，大火煮沸后，小火煎煮50-55分钟得到。
3.根据权利要求1所述的一种治疗猪黄白痢疾的中西药制剂，其特征在于，
青贮相思藤制作时，在花期，割取相思藤茎叶，浸渍于保鲜护色液中，并灌入真空度为200-220mm/Hg的罐内，贮存3个月以上得到。
4.根据权利要求3所述的一种治疗猪黄白痢疾的中西药制剂，其特征在于，
所述保鲜护色液由富碘卤水用阴离子交换膜和BPM-Ⅰ型双极膜组成的两隔室双极膜电渗析处理后得到，电渗析电压为22-26V，物料流量为8-9L/h。
5.根据权利要求1-4任意一项所述的一种治疗猪黄白痢疾的中西药制剂，其特征在于，
所述每g特制猪血清中含胆酸1.3-1.6mg，蛋白多糖5-5.5mg、表告依春2.6-3mg、β-谷甾醇1-1.5mg、角蛋白12-15mg、酪氨酸4.8-5mg。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710029015.4A CN106860857A (zh) | 2017-01-16 | 2017-01-16 | 一种治疗猪黄白痢疾的中西药制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710029015.4A CN106860857A (zh) | 2017-01-16 | 2017-01-16 | 一种治疗猪黄白痢疾的中西药制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106860857A true CN106860857A (zh) | 2017-06-20 |
Family
ID=59157572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710029015.4A Pending CN106860857A (zh) | 2017-01-16 | 2017-01-16 | 一种治疗猪黄白痢疾的中西药制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106860857A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112924633A (zh) * | 2021-05-10 | 2021-06-08 | 天津瑞普生物技术股份有限公司 | 一种头孢噻呋油混悬注射液的无菌检测方法 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1785317A (zh) * | 2005-11-11 | 2006-06-14 | 段朝学 | 治疗猪痢疾病的中西药复方粉剂 |
| CN101297793A (zh) * | 2008-05-13 | 2008-11-05 | 天津生机集团股份有限公司 | 用于治疗猪痢疾的注射液及其制备方法 |
| CN103007270A (zh) * | 2012-12-31 | 2013-04-03 | 蚌埠市畜牧兽医技术推广站 | 用于后海穴注射的治疗仔猪腹泻的注射剂 |
| CN103417703A (zh) * | 2013-09-09 | 2013-12-04 | 周冠旻 | 一种治疗猪痢疾的药物 |
| CN104147327A (zh) * | 2014-07-10 | 2014-11-19 | 河南恒野农牧股份有限公司 | 一种用于仔猪细菌性痢疾的药物制剂 |
| CN104586777A (zh) * | 2014-12-22 | 2015-05-06 | 广东省天宝生物制药有限公司 | 盐酸头孢噻呋粉针剂及其制备方法与应用 |
| CN104887806A (zh) * | 2015-05-27 | 2015-09-09 | 安徽恒源药业有限公司 | 一种治疗家禽痢疾的中药制剂 |
| CN105326794A (zh) * | 2015-10-28 | 2016-02-17 | 成都中牧生物药业有限公司 | 注射用头孢噻呋钠的制备工艺 |
| CN105748679A (zh) * | 2015-07-23 | 2016-07-13 | 安徽绿保源养殖有限公司 | 一种治疗猪热毒、痢疾的中药处方 |
-
2017
- 2017-01-16 CN CN201710029015.4A patent/CN106860857A/zh active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1785317A (zh) * | 2005-11-11 | 2006-06-14 | 段朝学 | 治疗猪痢疾病的中西药复方粉剂 |
| CN101297793A (zh) * | 2008-05-13 | 2008-11-05 | 天津生机集团股份有限公司 | 用于治疗猪痢疾的注射液及其制备方法 |
| CN103007270A (zh) * | 2012-12-31 | 2013-04-03 | 蚌埠市畜牧兽医技术推广站 | 用于后海穴注射的治疗仔猪腹泻的注射剂 |
| CN103417703A (zh) * | 2013-09-09 | 2013-12-04 | 周冠旻 | 一种治疗猪痢疾的药物 |
| CN104147327A (zh) * | 2014-07-10 | 2014-11-19 | 河南恒野农牧股份有限公司 | 一种用于仔猪细菌性痢疾的药物制剂 |
| CN104586777A (zh) * | 2014-12-22 | 2015-05-06 | 广东省天宝生物制药有限公司 | 盐酸头孢噻呋粉针剂及其制备方法与应用 |
| CN104887806A (zh) * | 2015-05-27 | 2015-09-09 | 安徽恒源药业有限公司 | 一种治疗家禽痢疾的中药制剂 |
| CN105748679A (zh) * | 2015-07-23 | 2016-07-13 | 安徽绿保源养殖有限公司 | 一种治疗猪热毒、痢疾的中药处方 |
| CN105326794A (zh) * | 2015-10-28 | 2016-02-17 | 成都中牧生物药业有限公司 | 注射用头孢噻呋钠的制备工艺 |
Non-Patent Citations (4)
| Title |
|---|
| 万端极等: "《轻工清洁生产》", 30 September 2006, 中国环境科学出版社 * |
| 吴化友: "仔猪腹泻的原因及防治技术探讨", 《畜牧兽医》 * |
| 春梅: "板蓝根治仔猪黄痢效果好", 《湖南农业》 * |
| 钱洪桂: "用猪血清治疗仔猪白痢病获得成功", 《浙江畜牧兽医》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112924633A (zh) * | 2021-05-10 | 2021-06-08 | 天津瑞普生物技术股份有限公司 | 一种头孢噻呋油混悬注射液的无菌检测方法 |
| CN112924633B (zh) * | 2021-05-10 | 2021-08-10 | 天津瑞普生物技术股份有限公司 | 一种头孢噻呋油混悬注射液的无菌检测方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101417018B (zh) | 一种具有清热解毒、凉血止痢功能的兽用注射剂的制备方法 | |
| CN103495136B (zh) | 一种治疗畜禽胃肠道寄生虫病的发酵中草药及其制备方法 | |
| CN101698011B (zh) | 治疗畜禽流行性腹泻的药物 | |
| CN103127198B (zh) | 治疗仔猪黄白痢的联合用药物 | |
| CN106860857A (zh) | 一种治疗猪黄白痢疾的中西药制剂 | |
| CN104352501A (zh) | 一种复方头孢噻呋钠注射剂 | |
| CN101590009A (zh) | 一种兽用替米考星及其盐的新型制剂及其制备方法 | |
| CN104523897B (zh) | 一种治疗仔猪流行性腹泻的灌肠药物组合物 | |
| CN101468057A (zh) | 一种用于治疗仔猪黄白痢的复方中药制剂 | |
| CN102793713A (zh) | 盐酸林可霉素-硫酸大观霉素注射液及其制备方法 | |
| CN101642460A (zh) | 用于治疗禽球虫感染的复方地克珠利溶液及其制备方法 | |
| CN101085076A (zh) | 防治兔球虫病中西药联合缓释注射剂及其制备方法 | |
| CN109316533B (zh) | 一种清除猪体内毒素的发酵中药复方制剂及其应用 | |
| CN103960466B (zh) | 一种以牧马豆为主料的饲料添加剂及其制作方法 | |
| CN1879736B (zh) | 禽类中药抗菌药物组合物及其制备方法 | |
| CN101953871A (zh) | 一种动物用抗菌药物及其制备方法和应用 | |
| CN101396427A (zh) | 一种用于治疗家禽病毒性肝炎及肝损伤的中药口服液 | |
| CN101966245B (zh) | 一种治疗畜禽病毒性疾病的复方注射液及其制备方法 | |
| RU2787754C1 (ru) | Способ лечения маститов крупного рогатого скота | |
| CN101543475B (zh) | 一种兽用泰妙菌素及其盐的肺靶向微球及其制备方法 | |
| CN101987108A (zh) | 一种驱除动物体内外寄生虫的复方注射剂及其制备方法 | |
| CN101249153A (zh) | 治疗禽类大肠杆菌疾病的中西药物及其制备方法 | |
| CN101297800B (zh) | 用于治疗犬类肝炎的复方牛磺酸可溶性粉及其制备方法 | |
| CN106236844A (zh) | 一种防治动物腹泻的药物组合物及其制备方法 | |
| CN100411637C (zh) | 一种治疗乳房炎的中兽药及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170620 |
|
| RJ01 | Rejection of invention patent application after publication |